Abstract

  Sunitinib and Ponatinib are two biological drugs that have greatly contributed to the treatment advances of different types of cancer. However, the ocular adverse effects of those drugs were not well studied and only a few case reports, within the literature, described patients who developed vision loss and ocular changes. In this study, we reported the clinical presentation of the first two Saudi patients presenting with a sudden loss of vision due to recent lines of treatment. The effect of these drugs has strongly implied the importance of cautious use and the need for further studies on their ocular side effects.

Keywords:Blindness; Ocular; Biological; Sunitinib; Ponatinib and Anticancer

References

1. Centre for Drug Evaluation and Research. “FDA Requires Multiple New Safety Measures for Leukaemia Drug (www.Iclusig.com)” U.S. Food and Drug Administration (2018)
2. Wegner A and R Khoramnia. “Neurosensory Retinal Detachment Due to Sunitinib Treatment”.  Eye 25.11 (2011): 1517-1518.
3. Fraunfelder Frederick T., et al. “Oral Anti-Vascular Endothelial Growth Factor Drugs and Ocular Adverse Events.” Mary Ann Liebert, Inc., Publishers 34.6 (2018): 632-635.
4. Elizondo Leal José A., et al. “Optic Neuropathy in Extramedullary, Blast Crisis of Chronic Myeloid Leukemia”. Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie, U.S. National Library of Medicine (2019).

Citation

Citation: Maaly Abdel Halim Abdel Fattah., et al. “Sudden Iatrogenic Blindness in Patients Treated with Biological Cancer Therapy”. Acta Scientific Ophthalmology 3.3 (2020): 01-03.

Copyright

Copyright: © 2020 Maaly Abdel Halim Abdel Fattah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.